Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
The newly FDA-approved nasal spray called Spravato is being manufactured by Johnson & Johnson's and is a standalone treatment ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...
The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder who have not responded to at least two oral antidepressants. This approval ...
The global landscape of neurological health is undergoing a transformative moment with a pioneering nasal spray that could potentially revolutionize Alzheimer‘s disease management. As ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...
Mumbai: Global pharma major Lupin Limited has announced that it has received tentative approval from the United States Food ...